Conditionally Replicating Viruses for Cancer Therapy

• US 20100316609A1
• Filed: 10/18/2007
• Published: 12/16/2010
• Est. Priority Date: 10/18/2006
• Status: Abandoned Application

• Current Assignee: University of Rochester
• Original Assignee: University of Rochester
• Inventors: Kim, Baek, Dewhurst, Stephen
• Application Number:
  US12/446,136
• Publication Number:
  US 20100316609A1
• Time in Patent Office: Days
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 9/1252 DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Abstract

Described herein are viral vectors comprising a nucleic acid encoding a viral DNA polymerase wherein the encoded viral DNA polymerase comprises at least one amino acid modification. Also provided are methods of making and using the viral vectors.

Claims

1. A viral vector comprising a nucleic acid encoding a viral DNA polymerase, wherein the encoded viral DNA polymerase comprises at least one amino acid mutation.

2. The viral vector of claim 1, wherein the viral vector is selected from the group consisting of adenoviral vectors, herpes simplex virus type-1 vectors, herpes simplex virus type-2 vectors, poxvirus vectors, lentiviral vectors, spumavirus vectors, and cytomegalovirus vectors.

4. The viral vector of claim 2, wherein the adenoviral vector is selected from the group consisting of an adenovirus type 3, adenovirus type 5, adenovirus type 7, adenovirus type 11, adenovirus type 19, adenovirus type 35, adenovirus type 49 and a non-human adenovirus vector.

5. The viral vector of claim 1, wherein the DNA polymerase is selected from the group consisting of an adenoviral DNA polymerase, a herpes simplex virus type-1 DNA polymerase, a herpes simplex virus type-2 DNA polymerase, a poxvirus DNA polymerase, a lentiviral DNA polymerase, a spumavirus DNA polymerase, and a cytomegalovirus DNA polymerase.

6. The viral vector of claim 5, wherein the adenoviral DNA polymerase is adenovirus type 5 DNA polymerase or an adenovirus type 19 DNA polymerase.

7. The viral vector of claim 6, wherein the mutation is an amino acid substitution selected from the group consisting of I664S, I664M, R665K, R833K, R833T, N841Y, N841S, Y844S, S692A, Y1010F, I664V, GG666/7AA, Y690A, Y690F and K837A.

8. The viral vector of claim 5, wherein the human lentiviral DNA polymerase is HIV-1 reverse transcriptase.

9. The viral vector of claim 8, wherein the mutation is an amino acid substitution selected from the group consisting of Q151N, V148I, A114V, A114L, A114S, Y115L, Y115M, Y115S, Y115V and Y115A.

10. The viral vector of claim 5, wherein the simian lentivirus DNA polymerase is simian immunodeficiency virus reverse transcriptase.

11. The viral vector of claim 10, wherein the mutation is amino acid substitution V148I.

12. The viral vector of claim 1, wherein the vector further comprises an essential viral gene operably linked to a tumor specific transcriptional promoter.

13. The viral vector of claim 1, wherein the vector further comprises a gene that functionally complements an essential viral gene and wherein the essential viral gene is non-functional.

14. The viral vector of claim 1, wherein the DNA polymerase is active at high dNTP concentrations.

15. The viral vector of claim 1, wherein the DNA polymerase is active at dNTP concentrations about 5 to 200 times higher than normal cellular dNTP concentrations.

16. The viral vector of claim 1, wherein the DNA polymerase shows 10 to 1000 fold lower activity at normal cellular dNTP concentrations as compared to its activity at high dNTP concentrations.

17. The viral vector of claim 1, wherein the vector further comprises a nucleic acid encoding a therapeutic polypeptide.

18. A pharmaceutical composition comprising the viral vector of claim 1 and a pharmaceutically acceptable carrier.

20. A method of treating cancer in a subject comprising administering to the subject the composition of claim 18.

21. The method of claim 20, further comprising administration of valproic acid or other histone deacetylase inhibitor (HDACi).

23. The method of claim 20, further comprising administration of radiation.

3. (canceled)

19. (canceled)

22. (canceled)

24. (canceled)

25. (canceled)